Are orforglipron's side effects different because it is a tablet?

No. The gastrointestinal profile follows from GLP-1 receptor pharmacology, not from route. The tablet removes dosing conditions and injection-site reactions, not nausea.

Why do multi-agonists report higher rates?

Engaging more receptors increases both the therapeutic effect and the mechanism-linked adverse effects. Larger effect sizes have consistently come with higher gastrointestinal burden.

How do I report a side effect in the UK?

Through the MHRA Yellow Card scheme, which accepts reports from healthcare professionals and from patients directly.

Orforglipron Side Effects and Tolerability Data

The short answer

The most commonly reported adverse effects of orforglipron are gastrointestinal: nausea, constipation, diarrhoea, vomiting, dyspepsia and abdominal pain. This profile is characteristic of GLP-1 receptor agonism generally rather than specific to orforglipron, and follows directly from how the receptor affects gastric emptying and satiety signalling.

Key facts

Most common effects: Nausea, constipation, diarrhoea, vomiting
Also reported: Dyspepsia, abdominal pain
Nature: Class effect across GLP-1 agonists
Mechanistic cause: Delayed gastric emptying, area postrema signalling
Typical pattern: Dose-related, most pronounced during escalation
Reporting route (UK): MHRA Yellow Card scheme

Why the effects are gastrointestinal

GLP-1 receptor agonism slows gastric emptying and acts on brainstem structures including the area postrema, which is central to both satiety and nausea. The therapeutic effect and the principal adverse effect therefore arise from the same mechanism rather than from an off-target action. This is why the profile is so consistent across the class regardless of chemistry. Peptide or not, injected or oral.

How this compares across the class

Gastrointestinal events dominate for every incretin compound reported to date. In retatrutide's TRIUMPH-1, nausea was reported by 42.4% on the 12 mg arm against 14.8% on placebo, and diarrhoea by 32.0% against 13.5%. Multi-agonists engaging more receptors generally report higher rates than GLP-1-only compounds, which is one of the trade-offs that comes with larger effect size.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £49.99

Discontinuation is the figure that matters

Incidence of an adverse event says less than how many people stopped because of one. TRIUMPH-1 reported 11.3% discontinuation due to adverse events on 12 mg against 4.9% on placebo. That number is frequently absent from summaries, and it is the one that connects tolerability to real-world outcome. A compound nobody can stay on does not deliver its trial result.

What the tablet format does and does not change

Being a tablet with no absorption enhancer removes the dosing conditions oral semaglutide carries, and removes injection-site reactions entirely. It does not change the gastrointestinal profile, because that follows from receptor pharmacology rather than route. A more convenient tablet is not automatically a better-tolerated drug.

Reporting suspected adverse effects in the UK

The MHRA operates the Yellow Card scheme for reporting suspected adverse drug reactions, defective medicines and falsified products. Reports can be submitted by healthcare professionals and by patients directly. It is also the correct route for reporting a suspected counterfeit GLP-1 product.

Frequently asked questions

Are orforglipron's side effects different because it is a tablet?: No. The gastrointestinal profile follows from GLP-1 receptor pharmacology, not from route. The tablet removes dosing conditions and injection-site reactions, not nausea.
Why do multi-agonists report higher rates?: Engaging more receptors increases both the therapeutic effect and the mechanism-linked adverse effects. Larger effect sizes have consistently come with higher gastrointestinal burden.
How do I report a side effect in the UK?: Through the MHRA Yellow Card scheme, which accepts reports from healthcare professionals and from patients directly.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction. That is the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer. It is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov, as the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

Orforglipron: Reported Side Effects and Tolerability